Today: 30 April 2026
Vistra stock rises after debt offering as Meta nuclear deal drives fresh price targets
13 January 2026
2 mins read

Vistra stock rises after debt offering as Meta nuclear deal drives fresh price targets

New York, Jan 12, 2026, 20:44 EST — Market closed

  • Shares of Vistra climbed 3.7% on Monday, building on the momentum from strong tech-sector electricity use.
  • The company kicked off a senior secured notes offering to back its planned acquisition of Cogentrix.
  • Traders are focused on debt pricing details and the estimated earnings date set for next month.

Shares of Vistra Corp. (VST.N) rose 3.7% to $172.58 on Monday, with roughly 7.2 million shares traded. Investors digested news of a new debt offering alongside fresh Wall Street mandates tied to its long-term nuclear power deal with Meta Platforms.

The stock is tied to a broader trend: Big Tech scrambling to secure electricity for data centers and AI tasks. Meta announced Friday it inked 20-year deals to buy power from three Vistra nuclear plants and will support small-reactor projects with Oklo and TerraPower. Joel Kaplan from Meta said these moves would “make Meta one of the most significant corporate purchasers of nuclear energy in American history.” Reuters

Vistra’s Meta contracts are power purchase agreements (PPAs) locking in long-term terms for selling electricity and grid capacity. They cover 2,609 megawatts from the company’s PJM nuclear fleet. According to a recent SEC filing, Vistra anticipates an 8% to 10% boost in adjusted free cash flow before growth accretion, tied to operating energy and capacity at full delivery. On top of that, there’s an expected additional 5% to 7% from “uprates,” which are upgrades that increase plant output. SEC

Vistra took a financing step Monday, unveiling a private offering of senior secured notes maturing in 2031 and 2036. The company intends to use the proceeds to help fund its earlier announced acquisition of Cogentrix, along with general corporate needs and debt repayment.

UBS bumped up its price target on Vistra to $233 from $230, maintaining a buy rating. The firm highlighted the Meta PPAs as a key factor supporting its confidence that Vistra can boost cash generation while leaving room to secure more long-term contracts. UBS also projected about $400 million in EBITDA growth from existing nuclear assets, plus another $400 million from uprates. Additionally, it pointed to PJM capacity prices at $330 per megawatt-day—payments for available power—as a solid foundation for “visible” long-term cash flow. Investing.com

Vistra is pushing ahead with a debt sale as it aims to finalize its $4.0 billion net purchase of Cogentrix Energy. The deal covers a portfolio of 10 natural-gas plants, totaling roughly 5,500 megawatts, spread across PJM, ISO New England, and ERCOT. The company said last week it anticipates closing the transaction in mid-to-late 2026, pending regulatory approvals.

Vistra is positioning its deal with Meta as a way to maintain current nuclear plants while boosting output incrementally. CEO Jim Burke described it as “a unique and exciting collaboration.” Meta’s Urvi Parekh emphasized the company’s commitment to nuclear power, calling it “clean, reliable power” essential for their AI goals. Vistra said deliveries start in late 2026, with more capacity coming online through 2034. Vistra Corp. Investor Relations

The upside scenario still hinges on smooth execution and regulatory approval. Delays in equipment upgrades, unexpected rises in capital costs, or issues renewing operating licenses could weigh on returns. Plus, the debt offering means some financing remains vulnerable to credit spread fluctuations.

Investors must also navigate power-market cycles that can shift quickly: while contracted revenue offers some stability, wholesale prices and grid capacity payments fluctuate, affecting how much they’re willing to pay for future cash flow.

Up next: the fine print on the note sale—details on size and pricing usually drop shortly after launch. Separately, Nasdaq’s earnings calendar lists Vistra’s report for Feb. 26, though the company hasn’t officially confirmed the date. That update will probably shift the conversation around 2026 cash flow and capital spending.

Stock Market Today

  • Wheat Prices Under Pressure as April Ends, USDA Lowers Crop Estimates
    April 30, 2026, 11:05 AM EDT. Wheat futures showed early losses Thursday morning as traders took profits before the end of April. Chicago SRW futures fell slightly, with open interest rising by 3,077 contracts. Kansas City HRW futures dropped, particularly May contracts ahead of the first notice day, while Minneapolis spring wheat posted modest gains. USDA's agricultural attaché revised down Australia's 2026/27 wheat crop to 29 million metric tons (MMT), 6 MMT below last year, and Canada's crop estimate also fell by 3.8 MMT to 36.16 MMT. Market watchers await export sales data for old and new crop wheat, expecting ranges between 0-300,000 MT and 0-200,000 MT respectively. Price swings reflect profit-taking alongside crop supply concerns amid shifting global outlooks.

Latest article

Mastercard Earnings Beat Wall Street, But April Cross-Border Slowdown Hits Stock

Mastercard Earnings Beat Wall Street, But April Cross-Border Slowdown Hits Stock

30 April 2026
Mastercard shares fell 2.7% Thursday despite first-quarter profit and revenue beating estimates, as investors reacted to slower April cross-border spending growth. Adjusted earnings reached $4.60 per share on $8.4 billion revenue. Cross-border volume growth dropped to 9% in April from 13% in Q1, with travel-linked growth at just 2%. Operating expenses rose 13%, including a $202 million restructuring charge.
Why Viavi Solutions Stock Is Surging After a Big Earnings Beat

Why Viavi Solutions Stock Is Surging After a Big Earnings Beat

30 April 2026
Viavi Solutions shares surged about 20% in early U.S. trading after fiscal third-quarter revenue rose 42.8% to $406.8 million, beating estimates. Adjusted earnings reached 27 cents per share, above forecasts. The company projected fourth-quarter revenue of $427 million to $437 million. GAAP profit declined from a year earlier and cash flow was negative for the quarter.
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land
Previous Story

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

Singapore Airlines stock slips as oil climbs on Iran fears; Feb 24 update looms
Next Story

Singapore Airlines stock slips as oil climbs on Iran fears; Feb 24 update looms

Go toTop